Vir Biotechnology, Inc. (VIR)
8.39
-0.48
(-5.41%)
USD |
NASDAQ |
Nov 20, 16:00
8.38
-0.01
(-0.12%)
After-Hours: 20:00
Vir Biotechnology Enterprise Value : 1.052B for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 1.052B |
| November 19, 2026 | 1.133B |
| November 18, 2026 | 1.181B |
| November 17, 2026 | 1.198B |
| November 16, 2026 | 1.253B |
| November 13, 2026 | 1.318B |
| November 12, 2026 | 1.684B |
| November 11, 2026 | 1.855B |
| November 10, 2026 | 1.858B |
| November 09, 2026 | 1.942B |
| November 06, 2026 | 1.699B |
| November 05, 2026 | 1.497B |
| November 04, 2026 | 1.624B |
| November 03, 2026 | 1.531B |
| November 02, 2026 | 1.494B |
| October 30, 2026 | 1.545B |
| October 29, 2026 | 1.621B |
| October 28, 2026 | 1.652B |
| October 27, 2026 | 1.591B |
| October 26, 2026 | 1.501B |
| October 23, 2026 | 1.421B |
| October 22, 2026 | 1.397B |
| October 21, 2026 | 1.421B |
| October 20, 2026 | 1.450B |
| October 19, 2026 | 1.360B |
| Date | Value |
|---|---|
| October 16, 2026 | 1.318B |
| October 15, 2026 | 1.404B |
| October 14, 2026 | 1.394B |
| October 13, 2026 | 1.428B |
| October 12, 2026 | 1.545B |
| October 09, 2026 | 1.613B |
| October 08, 2026 | 1.514B |
| October 07, 2026 | 1.582B |
| October 06, 2026 | 1.596B |
| October 05, 2026 | 1.626B |
| October 02, 2026 | 1.523B |
| October 01, 2026 | 1.543B |
| September 30, 2026 | 1.525B |
| September 29, 2026 | 1.360B |
| September 28, 2026 | 1.337B |
| September 25, 2026 | 1.362B |
| September 24, 2026 | 1.372B |
| September 23, 2026 | 1.435B |
| September 22, 2026 | 1.504B |
| September 21, 2026 | 1.399B |
| September 18, 2026 | 1.352B |
| September 17, 2026 | 1.406B |
| September 16, 2026 | 1.338B |
| September 15, 2026 | 1.325B |
| September 14, 2026 | 1.380B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 77.84B |
| Vaxcyte, Inc. | 7.199B |
| Oncolytics Biotech, Inc. | 44.27M |
| Sangamo Therapeutics, Inc. | 35.66M |
| Sarepta Therapeutics, Inc. | 1.604B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -96.25M |
| Revenue (Quarterly) | -0.188M |
| Total Expenses (Quarterly) | 96.06M |
| EPS Diluted (Quarterly) | -0.5686 |
| Earnings Yield | -14.97% |
| Normalized Earnings Yield | -14.76 |